170 related articles for article (PubMed ID: 19917065)
1. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats.
Stroes ES; Kastelein JJ; Bénardeau A; Kuhlmann O; Blum D; Campos LA; Clerc RG; Niesor EJ
Br J Pharmacol; 2009 Dec; 158(7):1763-70. PubMed ID: 19917065
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Clerc RG; Stauffer A; Weibel F; Hainaut E; Perez A; Hoflack JC; Bénardeau A; Pflieger P; Garriz JM; Funder JW; Capponi AM; Niesor EJ
J Hypertens; 2010 Aug; 28(8):1676-86. PubMed ID: 20498617
[TBL] [Abstract][Full Text] [Related]
3. Torcetrapib impairs endothelial function in hypertension.
Simic B; Hermann M; Shaw SG; Bigler L; Stalder U; Dörries C; Besler C; Lüscher TF; Ruschitzka F
Eur Heart J; 2012 Jul; 33(13):1615-24. PubMed ID: 21920972
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of dalcetrapib.
Stein EA; Stroes ES; Steiner G; Buckley BM; Capponi AM; Burgess T; Niesor EJ; Kallend D; Kastelein JJ
Am J Cardiol; 2009 Jul; 104(1):82-91. PubMed ID: 19576325
[TBL] [Abstract][Full Text] [Related]
5. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.
Forrest MJ; Bloomfield D; Briscoe RJ; Brown PN; Cumiskey AM; Ehrhart J; Hershey JC; Keller WJ; Ma X; McPherson HE; Messina E; Peterson LB; Sharif-Rodriguez W; Siegl PK; Sinclair PJ; Sparrow CP; Stevenson AS; Sun SY; Tsai C; Vargas H; Walker M; West SH; White V; Woltmann RF
Br J Pharmacol; 2008 Aug; 154(7):1465-73. PubMed ID: 18536749
[TBL] [Abstract][Full Text] [Related]
6. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
Stein EA; Roth EM; Rhyne JM; Burgess T; Kallend D; Robinson JG
Eur Heart J; 2010 Feb; 31(4):480-8. PubMed ID: 20097702
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of cholesteryl ester transfer protein inhibitors.
Ranalletta M; Bierilo KK; Chen Y; Milot D; Chen Q; Tung E; Houde C; Elowe NH; Garcia-Calvo M; Porter G; Eveland S; Frantz-Wattley B; Kavana M; Addona G; Sinclair P; Sparrow C; O'Neill EA; Koblan KS; Sitlani A; Hubbard B; Fisher TS
J Lipid Res; 2010 Sep; 51(9):2739-52. PubMed ID: 20458119
[TBL] [Abstract][Full Text] [Related]
11. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC
Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
[TBL] [Abstract][Full Text] [Related]
12. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
Hu X; Dietz JD; Xia C; Knight DR; Loging WT; Smith AH; Yuan H; Perry DA; Keiser J
Endocrinology; 2009 May; 150(5):2211-9. PubMed ID: 19164467
[TBL] [Abstract][Full Text] [Related]
13. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
Rios FJ; Neves KB; Nguyen Dinh Cat A; Even S; Palacios R; Montezano AC; Touyz RM
J Pharmacol Exp Ther; 2015 Apr; 353(1):27-34. PubMed ID: 25617244
[TBL] [Abstract][Full Text] [Related]
14. The influence of multiple oral administration on the pharmacokinetics and distribution profile of dalcetrapib in rats.
Takubo H; Ishikawa T; Taniguchi T; Iwanaga K; Nomura Y
Xenobiotica; 2021 Jan; 51(1):82-87. PubMed ID: 32783571
[TBL] [Abstract][Full Text] [Related]
15. Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
Niesor EJ; Chaput E; Staempfli A; Blum D; Derks M; Kallend D
Atherosclerosis; 2011 Dec; 219(2):761-7. PubMed ID: 21982411
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Fayad ZA; Mani V; Woodward M; Kallend D; Abt M; Burgess T; Fuster V; Ballantyne CM; Stein EA; Tardif JC; Rudd JH; Farkouh ME; Tawakol A;
Lancet; 2011 Oct; 378(9802):1547-59. PubMed ID: 21908036
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin-aldosterone responsiveness to low sodium and blood pressure reactivity to angiotensin-II are unrelated to cholesteryl ester transfer protein mass in healthy subjects.
Krikken JA; Dallinga-Thie GM; Navis G; Dullaart RP
Expert Opin Ther Targets; 2008 Nov; 12(11):1321-8. PubMed ID: 18851690
[TBL] [Abstract][Full Text] [Related]
18. Monitoring Cyp2b10 mRNA expression at cessation of 2-year carcinogenesis bioassay in mouse liver provides evidence for a carcinogenic mechanism devoid of human relevance: the dalcetrapib experience.
Hoflack JC; Mueller L; Fowler S; Braendli-Baiocco A; Flint N; Kuhlmann O; Singer T; Roth A
Toxicol Appl Pharmacol; 2012 Mar; 259(3):355-65. PubMed ID: 22293087
[TBL] [Abstract][Full Text] [Related]
19. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
20. The end of the road for CETP inhibitors after torcetrapib?
Joy T; Hegele RA
Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
